FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/04/024947 [Registered on: 30/04/2020] Trial Registered Prospectively
Last Modified On: 30/04/2020
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Homeopathy 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Clinical trial on effects of homeopathic medicine made from cadamba on COVID-19 
Scientific Title of Study   Drug Proving & checking its effectiveness in treatment of COVID 19 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Prashant katre 
Designation  Doctor 
Affiliation  Homoeo clinic  
Address  dr katre house homoeo clinic civil line
homoeo clinic civil line
Gondiya
MAHARASHTRA
441601
India 
Phone  9325259285  
Fax    
Email  priti.katre@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prashant katre 
Designation  Doctor 
Affiliation  Homoeo clinic  
Address  dr katre house homoeo clinic civil line
homoeo clinic civil line
Gondiya
MAHARASHTRA
441601
India 
Phone  9325259285  
Fax    
Email  priti.katre@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Prashant katre 
Designation  Doctor 
Affiliation  Homoeo clinic  
Address  dr katre house homoeo clinic civil line
homoeo clinic civil line
Gondiya
MAHARASHTRA
441601
India 
Phone  9325259285  
Fax    
Email  priti.katre@gmail.com  
 
Source of Monetary or Material Support  
at present in basic level i have arranged raw material on my own  
 
Primary Sponsor  
Name  Dr Priti katre 
Address  Homoeo clinic civil line locoshed road Gondia Maharashtra 441601 
Type of Sponsor  Private hospital/clinic 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Prashant katre  homoeo clinic   Gondia homeopathic institute surya tola Gondia Maharashtra
Gondiya
MAHARASHTRA 
9325259285

priti.katre@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Gondia homoeopathic medical college and hospital research ethic review committee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  B972||Coronavirus as the cause of diseases classified elsewhere,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  cadamba drug therapy  1st 3 days 6 doses in every 2 hours QID 3 days then TDS for weeks potency 200  
 
Inclusion Criteria  
Age From  1.00 Day(s)
Age To  90.00 Year(s)
Gender  Both 
Details  1 COVID affected individual (serologically positive) symptomatic, mild hospitalized
2 asymptomatic (serologically positive) 
 
ExclusionCriteria 
Details  1.Malabsorption or inadequate oral intake
2.unexplained, chronic diarrhea, defined as more than 3 loose stool per day persisting for 2 weeks or more within the month prior to study entry.
3. Active malignancy or anticipated need for chemotherapy during the study 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Other 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
with refrance to time scale T1-T4 --
from 5-7 weeks we expect complete recovery of patient who presented with initial symptoms.
1 patient should be asymptomatic with gental recovery (with serologically negative blood test) within 7-14 days after administration of 1st dose of medicine.
2 asymptomatic patient (serologically positive) will remain asymptomatic and should be serologically negative after 7-14 days of treatment. 
with refrance to time scale T1-T4 --
from 5-8 weeks we expect complete recovery of patient who presented with initial symptoms.  
 
Secondary Outcome  
Outcome  TimePoints 
with refrance to time scale T1-T5
if patient have late symptoms with initial pathological changes in vital organs we expect recovery by day 14
1 we can conclude after the study is complete.
 
(T1 to T5)
T1- presentation before medicine intake.
T2- observation for 1-3 days after drug intake.
T3- 3 to 7days gradual disappearance of initial symptoms.
T4- after 7 days recovery expected.
T5- If associated with other secondary complaints expected recovery is by 7-14 days. 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   08/05/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   nil 
Brief Summary   chemical components of this drug help us to resolve ·        
Anti-viral

·        Anti-inflammatory

·         Anti-pyretic

·         Anti-diarrheal

·         Wound healing properties

·         Strong immuno-modulator

Blood purifier   
also the raw material of drug resembles to that of the virus which full fills the criteria of homoeopathy that is doctrine of signature 
so i hope this drug of mine can help us fight covid 19 pandemic
 
Close